Literature DB >> 18835977

The limited role of midnight salivary cortisol levels in the diagnosis of subclinical hypercortisolism in patients with adrenal incidentaloma.

Benedetta Masserini1, Valentina Morelli, Silvia Bergamaschi, Federica Ermetici, Cristina Eller-Vainicher, Anna Maria Barbieri, Maria Antonia Maffini, Alfredo Scillitani, Bruno Ambrosi, Paolo Beck-Peccoz, Iacopo Chiodini.   

Abstract

OBJECTIVE: The criteria for defining subclinical hypercortisolism (SH) are debated and a real gold standard test or combination of tests is lacking. Recently, late-night salivary cortisol (MSC) has been described as a sensitive and easy-to-perform marker for diagnosing overt hypercortisolism. No data are available on the role of MSC in the diagnosis of SH. The aim of this study was to evaluate the sensitivity and specificity of MSC levels in the diagnosis of SH in patients with adrenal incidentalomas (AI).
METHODS: In 103 (females/males, 69/34) patients with AI, MSC levels were studied. One milligram overnight dexamethasone suppression test (DST), urinary-free cortisol (UFC), and ACTH plasma levels were also evaluated. Patients were defined as affected by SH if they showed two of the following criteria: DST>83 nmol/l, ACTH <2.2 pmol/l, and UFC >193 nmol/24 h.
RESULTS: No difference in MSC levels in patients with SH (3.1+/-3.1 nmol/l) compared with patients without SH (2.2+/-2.8 nmol/l) was observed. In patients with SH, MSC levels were significantly correlated with DST (r=0.4, P<0.05). Using the cut-off of 5.1 nmol/l, the sensitivity and specificity of MSC levels for diagnosis of SH is 22.7 and 87.7% respectively.
CONCLUSION: In patients with AI, normal levels of MSC do not exclude SH, whereas high levels may suggest the presence of SH identified by conventional tests. Thus, MSC is not suitable as a screening test, although it may be used in conjunction with other tests as the confirming test in selected patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18835977     DOI: 10.1530/EJE-08-0485

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  29 in total

Review 1.  Cushing's syndrome: diagnosis and surveillance using salivary cortisol.

Authors:  Hershel Raff
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

Review 2.  Pros and cons of screening for occult Cushing syndrome.

Authors:  Antoine Tabarin; Paul Perez
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

Review 3.  Update on late-night salivary cortisol for the diagnosis of Cushing's syndrome: methodological considerations.

Authors:  Hershel Raff
Journal:  Endocrine       Date:  2013-07-10       Impact factor: 3.633

Review 4.  Reliability of hypothalamic-pituitary-adrenal axis assessment methods for use in population-based studies.

Authors:  Sherita Hill Golden; Gary S Wand; Saurabh Malhotra; Ihab Kamel; Karen Horton
Journal:  Eur J Epidemiol       Date:  2011-04-30       Impact factor: 8.082

5.  DHEAS for the prediction of subclinical Cushing's syndrome: perplexing or advantageous?

Authors:  Serkan Yener; Hamiyet Yilmaz; Tevfik Demir; Mustafa Secil; Abdurrahman Comlekci
Journal:  Endocrine       Date:  2014-08-22       Impact factor: 3.633

6.  Cardiometabolic profile of non-functioning and autonomous cortisol-secreting adrenal incidentalomas. Is the cardiometabolic risk similar or are there differences?

Authors:  Marta Araujo-Castro; Cristina Robles Lázaro; Paola Parra Ramírez; Martín Cuesta Hernández; Miguel Antonio Sampedro Núñez; Mónica Marazuela
Journal:  Endocrine       Date:  2019-08-31       Impact factor: 3.633

7.  Daily salivary cortisol and cortisone rhythm in patients with adrenal incidentaloma.

Authors:  Filippo Ceccato; Mattia Barbot; Nora Albiger; Giorgia Antonelli; Marialuisa Zilio; Marco Todeschini; Daniela Regazzo; Mario Plebani; Carmelo Lacognata; Maurizio Iacobone; Franco Mantero; Marco Boscaro; Carla Scaroni
Journal:  Endocrine       Date:  2017-09-27       Impact factor: 3.633

Review 8.  Autonomous cortisol secretion in adrenal incidentalomas.

Authors:  Marta Araujo-Castro; Miguel Antonio Sampedro Núñez; Mónica Marazuela
Journal:  Endocrine       Date:  2019-03-07       Impact factor: 3.633

9.  First-line screening tests for Cushing's syndrome in patients with adrenal incidentaloma: the role of urinary free cortisol measured by LC-MS/MS.

Authors:  F Ceccato; G Antonelli; A C Frigo; D Regazzo; M Plebani; M Boscaro; C Scaroni
Journal:  J Endocrinol Invest       Date:  2017-02-28       Impact factor: 4.256

10.  The diagnostic accuracy of increased late night salivary cortisol for Cushing's syndrome: a real-life prospective study.

Authors:  F Ceccato; G Marcelli; M Martino; C Concettoni; M Brugia; L Trementino; G Michetti; G Arnaldi
Journal:  J Endocrinol Invest       Date:  2018-07-09       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.